Search

Your search keyword '"Maul, Julia-Tatjana' showing total 14 results
Start Over Author "Maul, Julia-Tatjana Publisher wiley
14 results on '"Maul, Julia-Tatjana'

1. Patient and dermatologists' perspectives on augmented intelligence for melanoma screening: A prospective study

Author

Goessinger, Elisabeth Victoria, primary, Niederfeilner, Johannes‐Christian, additional, Cerminara, Sara, additional, Maul, Julia‐Tatjana, additional, Kostner, Lisa, additional, Kunz, Michael, additional, Huber, Stephanie, additional, Koral, Emrah, additional, Habermacher, Lea, additional, Sabato, Gianna, additional, Tadic, Andrea, additional, Zimmermann, Carmina, additional, Navarini, Alexander, additional, and Maul, Lara Valeska, additional

Published
2024
Full Text
View/download PDF

2. Sex differences in adverse events from systemic treatments for psoriasis: A decade of insights from the Swiss Psoriasis Registry (SDNTT)

Author

Verardi, Fabio, primary, Maul, Lara Valeska, additional, Borsky, Kim, additional, Steinmann, Simona, additional, Rosset, Nina, additional, Pons, Hector Ortega, additional, Sorbe, Christina, additional, Yawalkar, Nikhil, additional, Micheroli, Raphael, additional, Egeberg, Alexander, additional, Thyssen, Jacob P., additional, Heidemeyer, Kristine, additional, Boehncke, Wolf‐Henning, additional, Conrad, Curdin, additional, Cozzio, Antonio, additional, Pinter, Andreas, additional, Kündig, Thomas, additional, Navarini, Alexander A., additional, and Maul, Julia‐Tatjana, additional

Published
2023
Full Text
View/download PDF

4. S2k guideline diagnosis, prevention, and therapy of hand eczema

Author

Bauer, Andrea, primary, Brans, Richard, additional, Brehler, Randolf, additional, Büttner, Marion, additional, Dickel, Heinrich, additional, Elsner, Peter, additional, Fartasch, Manigé, additional, Herzog, Claudia, additional, John, Swen‐Malte, additional, Köllner, Arno, additional, Maul, Julia‐Tatjana, additional, Merk, Hans, additional, Molin, Sonja, additional, Nast, Alexander, additional, Nikolakis, Georgios D., additional, Schliemann, Sybille, additional, Skudlik, Christoph, additional, Weisshaar, Elke, additional, Werfel, Thomas, additional, Zidane, Miriam, additional, and Worm, Margitta, additional

Published
2023
Full Text
View/download PDF

5. S2k‐Leitlinie Diagnostik, Prävention und Therapie des Handekzems

Author

Bauer, Andrea, primary, Brans, Richard, additional, Brehler, Randolf, additional, Büttner, Marion, additional, Dickel, Heinrich, additional, Elsner, Peter, additional, Fartasch, Manigé, additional, Herzog, Claudia, additional, John, Swen‐Malte, additional, Köllner, Arno, additional, Maul, Julia‐Tatjana, additional, Merk, Hans, additional, Molin, Sonja, additional, Nast, Alexander, additional, Nikolakis, Georgios D., additional, Schliemann, Sybille, additional, Skudlik, Christoph, additional, Weisshaar, Elke, additional, Werfel, Thomas, additional, Zidane, Miriam, additional, and Worm, Margitta, additional

Published
2023
Full Text
View/download PDF

8. Anti‐drug antibodies of IL‐23 inhibitors for psoriasis: a systematic review

Author

Norden, A, Moon, J Y, Javadi, S S, Munawar, L, Maul, Julia-Tatjana, Wu, J J, University of Zurich, and Wu, J J

Subjects
2708 Dermatology, Infectious Diseases, 10177 Dermatology Clinic, Humans, Interleukin Inhibitors, Psoriasis, 610 Medicine & health, 2725 Infectious Diseases, Dermatology, Antibodies, Neutralizing, Interleukin-23
Abstract

Anti-drug antibodies (ADAs) can form with certain biological medications, but their clinical significance is not fully understood. ADA formation in psoriasis patients treated with IL-23 inhibitors was evaluated, looking at the incidence of ADAs, impact on clinical outcomes and association with adverse events. A systematic search of PubMed, Cochrane and Embase databases yielded 318 articles, which were manually reviewed. A total of 19 articles met the eligibility criteria. The incidence of ADAs with the IL-23 inhibitors was as follows: 4.1-14.7% with guselkumab, 141-31% with risankizumab and 6.51-18% with tildrakizumab. The incidence of neutralizing antibodies ranged from 01-0.6% with guselkumab, 21-16% with risankizumab and 2.5 to 3.2% with tildrakizumab. There was no evidence of reduced efficacy of psoriasis treatment with ADA presence alone. However, some studies found a reduction in clinical response with high ADA titres or with the presence of neutralizing antibodies. A few studies reported that patients with ADAs to guselkumab and risankizumab had a higher incidence of injection site reactions (ISRs). There do not appear to be other adverse events associated with ADAs with IL-23 inhibitors. Testing for presence of ADAs alone in this patient group does not appear to be predictive of treatment response. Clinically, it may be more productive to test for neutralizing antibodies or ADA titre values, although further investigation is required to show a definitive correlation.

Published
2022
Full Text
View/download PDF

13. Efficacious and save use of biosimilar filgrastim for hematopoietic progenitor cell chemo-mobilization with vinorelbine in multiple myeloma patients

Author

Maul, Julia-Tatjana, primary, Stenner-Liewen, Frank, additional, Seifert, Burkhardt, additional, Pfrommer, Sarah, additional, Petrausch, Ulf, additional, Kiessling, Michael K., additional, Schanz, Urs, additional, Nair, Gayathri, additional, Mischo, Axel, additional, Taverna, Christian, additional, Schmidt, Adrian, additional, Bargetzi, Mario, additional, Stupp, Roger, additional, Renner, Christoph, additional, and Samaras, Panagiotis, additional

Published
2016
Full Text
View/download PDF

14. Prevalence and Characteristics of Chronic Hand Eczema Among Adults in Denmark: A General Population-Based Study.

Author

Thein D, Maul JT, Ribero S, Silverberg JI, Egeberg A, and Thyssen JP

Abstract

Background: The epidemiology of chronic hand eczema (CHE) remains poorly examined., Objective: To investigate the prevalence of CHE in a general adult population and describe the characteristics of affected individuals., Methods: We investigated the prevalence and characteristics of CHE using a random sample from the general Danish population (The Danish Skin Cohort). CHE was defined as eczema on the hands or wrists during a minimum of three consecutive months or reoccurrence of hand eczema at least twice within 12 months., Results: Out of 11 166 adults, 1306 experienced hand eczema (HE) at some point in their lifetime. Within the last 12 months, 408 (3.7%) experienced HE, of which 332 (81.4%) reported CHE. The crude 1-year period prevalence of CHE was 3.0% (95% confidence interval (CI), 2.7%-3.3%) while the standardised prevalence was 3.5% (95% CI, 3.3%-3.6%). Among adults with CHE, 70.8% were female, and the mean age was 48.0 years (standard deviation 16.6 years). Most individuals with CHE had two relapses (n = 309, 93.1%), while n = 206, 61.1%, had HE for more than 3 months. Compared to HE, CHE was more likely diagnosed by a dermatologist and affect the fingers and back of the hand., Conclusion: The standardised prevalence was 3.5% (95% CI, 3.3%-3.6%) and 4.2% (95% CI, 4.0%-4.4%) for CHE and HE, respectively. We identified a large overlap between HE and CHE (81.4%) in adults from the general population, indicating that many individuals affected by eczema on the hands may experience a chronic course., (© 2025 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)

Published
2025
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results